Catrin O. Plumpton

Bangor, NIR, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Cost-effectiveness of screening for developmental dysplasia of the hip in children born in England and Wales.

Cost-effectiveness of screening for developmental dysplasia of the hip in children born in England and Wales.

Journal: The bone & joint journal
Published: July 31, 2026

Parental preferences for brace weaning in developmental dysplasia of the hip: a discrete choice experiment.

Parental preferences for brace weaning in developmental dysplasia of the hip: a discrete choice experiment.

Journal: Bone & joint open
Published: December 10, 2025

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics.

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics.

Journal: British journal of clinical pharmacology
Published: August 20, 2025

Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales.

Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales.

Journal: British journal of clinical pharmacology
Published: August 20, 2025

Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis.

Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis.

Journal: BMJ open
Published: May 09, 2025

Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.

Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.

Journal: Health technology assessment (Winchester, England)
Published: December 21, 2021

Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial.

Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial.

Journal: JMIR research protocols
Published: October 27, 2021

Linear mixed models to handle missing at random data in trial-based economic evaluations.

Linear mixed models to handle missing at random data in trial-based economic evaluations.

Journal: Health economics
Published: July 22, 2021

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Journal: Lancet (London, England)
Published: November 16, 2020

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Journal: Lancet (London, England)
Published: November 16, 2020

Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).

Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).

Journal: BMJ open
Published: August 28, 2020

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.

Journal: Health technology assessment (Winchester, England)
Published: April 30, 2019
Showing 1-12 of 35

Last Updated: 09/26/2026